Investment analysts at Jefferies Financial Group initiated coverage on shares of Legend Biotech (NASDAQ:AMTI) in a research report issued on Tuesday, Briefing.com Automated Import reports. The brokerage set a “buy” rating and a $38.00 price target on the stock. Jefferies Financial Group’s target price suggests a potential upside of 45.32% from the company’s current price.
A number of other research firms have also weighed in on AMTI. BofA Securities started coverage on shares of Legend Biotech in a research report on Tuesday. They set a “buy” rating and a $34.00 price target on the stock. Bank of America started coverage on shares of Legend Biotech in a report on Tuesday. They set a “buy” rating for the company. Finally, SVB Leerink started coverage on shares of Legend Biotech in a report on Tuesday. They set an “outperform” rating and a $32.00 price objective for the company.
AMTI opened at $26.15 on Tuesday. Legend Biotech has a fifty-two week low of $17.05 and a fifty-two week high of $31.84.
Applied Molecular Transport Inc develops biological therapeutics to treat autoimmune, metabolic, and inflammatory diseases.. The company develops submucosal biopharmaceuticals and bio-betters. Applied Molecular Transport Inc was incorporated in 2010 and is based in South San Francisco, California.
Featured Story: What is the Rule of 72?
Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.